Alamo Group's investment case hinges on its ability to navigate a decelerating replacement cycle while integrating recent acquisitions. The company maintains a fortress balance sheet with a D/E of 0.23 and ample liquidity (current ratio 4.39), providing flexib...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $2.57-6.2% vs $2.74 | $451M+3.0% vs $437M |
Q2 2026 May 4, 2026 | $2.42+12.6% vs $2.15 | $417M+4.8% vs $398M |
Q2 2026 Mar 2, 2026 | $1.70-17.5% vs $2.06 | $374M-7.2% vs $403M |
Q4 2025 Nov 6, 2025 | $2.34-10.3% vs $2.61 | $420M+3.7% vs $405M |
Alamo Group (NYSE: ALG - Get Free Report) and Timken (NYSE: TKR - Get Free Report) are both mid-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership and risk. Dividends Alamo Group pays an annual dividend of
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), who maintain rights in Greater China.
Deere, Kubota, CNH, AGCO and Alamo have been highlighted in this Industry Outlook article.
Alamo Group Inc. (ALG) Q2 2026 Earnings Call Transcript
Benchmark ALG against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Alamo Group Inc. (ALG)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $165.51 | $2.01B | 19.27 | -1.52% | 6.47% | 9.58% | 0.72% | |
| $42.28 | $972.13M | 25.17 | 8.07% | 1.26% | 2.88% | — | |
| $68.66 | $2.27B | 47.35 | 4.11% | 8.01% | 7.65% | — | |
| $68.44 | $4.17B | 18.40 | 3.71% | 5.75% | 7.51% | — | |
| $15.31 | $639.41M | 773.23 | -43.3% | 1.79% | 0.68% | — | |
| $703.12 | $189.8B | 38.01 | -11.59% | 10.22% | 18.07% | — |
Alamo Group Inc. (ALG) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Alamo Group Inc. (ALG) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 8, 2026·SEC
May 28, 2026·SEC
Get notified when ALG posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Alamo Group Inc. (ALG) stock FAQ — growth, dividends, profitability & financials explained
Alamo Group Inc. (ALG) reported $1.66B in revenue for fiscal year 2025. This represents a 805% increase from $183.6M in 1996.
Alamo Group Inc. (ALG) saw revenue decline by 1.5% over the past year.
Yes, Alamo Group Inc. (ALG) is profitable, generating $101.0M in net income for fiscal year 2025 (6.5% net margin).
Yes, Alamo Group Inc. (ALG) pays a dividend with a yield of 0.72%. This makes it attractive for income-focused investors.
Alamo Group Inc. (ALG) has a return on equity (ROE) of 9.6%. This is below average, suggesting room for improvement.
Alamo Group Inc. (ALG) generated $135.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
